Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.6600 -0.0462 (-6.54%)
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter
Via Investor Brand Network
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
Via Investor Brand Network
Silo Pharma Extends Alzheimer's Therapeutics Research Pact
 
Via Benzinga
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
From Silo Pharma, Inc.
Via GlobeNewswire
7 Millionaire-Maker Stocks You Will Regret Not Buying This Year
With the market shifting toward a deflationary stance, investors should target these robust millionaire-maker stocks to buy. 
Via InvestorPlace
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu 
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
Via Investor Brand Network
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
From Silo Pharma, Inc.
Via GlobeNewswire
New Psychedelic Journal to Focus on Publishing Psychedelic Research
Via Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
Via Investor Brand Network
Microscopy Provides Insights on Psychedelics Action Inside Neuropathways
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector
Via Investor Brand Network
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
Via Investor Brand Network
What You Should Know About Colorado’s Psychedelics Ballot Measure
Via Investor Brand Network
Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
Via Investor Brand Network
What Is Going on With Silo Pharma (SILO) Stock Today?
Silo Pharma (SILO) stock is falling on Thursday despite the company releasing positive data from a pre-clinical Alzheimer's study. 
Via InvestorPlace
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Dosing study of SPC-14 demonstrates efficacy for increasing memory function Englewood Cliffs, NJ – October 20, 2022 – Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage... 
Via FinancialNewsMedia
Silo Pharma Posts Encouraging Preclinical Data For Alzheimer's Candidate
Silo Pharma Inc (NASDAQ: SILO) has announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD). The research was conducted as part of a... 
Via Benzinga
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Dosing study of SPC-14 demonstrates efficacy for increasing memory function 
From Silo Pharma, Inc.
Via GlobeNewswire
Psychedelics For Alzheimer's And Stress-Induced Disorders Under Study At Columbia University
Silo Pharma Inc. 
Via Benzinga
Florida Dispensary Uncovers Legal Loophole, Starts Selling Shrooms
Via Investor Brand Network
Topics Law Enforcement
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extent Research Pact
Via Investor Brand Network
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
Silo and Columbia University continue research on SPC-14 for Alzheimer’s and SPC-15 for Stress Induced Disorders 
From Silo Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Silo Pharma Stock Higher After Investors Appraise Innovative Treatment For Nerve Pain And Neurological Disorders ($SILO)
Via AB Newswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.